Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Investors and analysts are urging Novo Nordisk CEO Mike Doustdar to outline the company's strategy beyond its blockbuster weight-loss drug Wegovy, calling for medium-term targets and acquisitions to counter looming patent cliffs and competition from Eli Lilly.
CEO Mike Doustdar will face pressure Monday to outline how Novo Nordisk will compete with US rival Eli Lilly and boost growth beyond Wegovy.
Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company's obesity strategy While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat on its amylin-based drug petrelintide An emerging theme in the weight loss space is the growing acknowledgement of the nee
Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company's obesity strategy While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat on its amylin-based drug petrelintide An emerging theme in the weight loss space is the growing acknowledgement of the nee